artificial intelligenceAI in clinical research: hype vs. realityAI can already reduce administrative work, improve decision-making and streamline parts of clinical development. But its impact is often overstated. Evidenze’s Raphaela Schnurbus explains where AI … more ➔
artificial intelligenceClosing AI medicine’s manufacturing gapAt the IZB in Martinsried, Invitris is developing a cell-free platform to turn digital sequences into proteins, antibodies and phages within hours. CEO Patrick Grossmann explains why AI is shifting … more ➔
CRO & CDMOFrom development to commercial realityHelping biopharmaceutical innovators build scalable, manufacturable, and commercially viable processes from the start. more ➔
autoimmune diseaseAATec is pioneering a new approach to lung diseasesAATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for chronic respiratory diseases. Rüdiger Jankowsky, CEO, and Gabriele Matschiner, … more ➔
BiosimilarsPerfusion for next generation biosimilarsPerfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially … more ➔
CRO & CDMOEvery process is different. Not the platform.For CDMOs, flexible upstream platforms can help streamline process development while maintaining reproducibility and continuity across scales. more ➔
CRO & CDMODesigning biologics for commercial successJustyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readin … more ➔
New England BiolabsThe Bridge to your successCustomized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product. more ➔
Cell & Gene TherapyEurope’s CGT advantage at riskIndustry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global … more ➔
intellectual propertyG 1/25: Form over function and how expensive is it?In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation … more ➔
